Bayer: Q2 EPS down 23%
(CercleFinance.com) - Bayer has reported Q2 2024 adjusted EPS that is down 23% to E0.
94, with EBITDA before non-recurrent items down 16.5% to E2.11bn, a decline which it says is mainly attributable to an unfavourable product mix.
At over E11.1bn, the German group's sales nevertheless rose by 3.1%, driven by its three main divisions: pharmaceuticals (+4.5%), consumer health care (+5.3%) and, secondarily, agrochemicals (+1.1%).
Announcing good progress on its strategic priorities and advances in innovation, particularly in the pharmaceuticals division, Bayer confirms its annual targets at the group level, while adjusting them at the divisional level.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
94, with EBITDA before non-recurrent items down 16.5% to E2.11bn, a decline which it says is mainly attributable to an unfavourable product mix.
At over E11.1bn, the German group's sales nevertheless rose by 3.1%, driven by its three main divisions: pharmaceuticals (+4.5%), consumer health care (+5.3%) and, secondarily, agrochemicals (+1.1%).
Announcing good progress on its strategic priorities and advances in innovation, particularly in the pharmaceuticals division, Bayer confirms its annual targets at the group level, while adjusting them at the divisional level.
Copyright (c) 2024 CercleFinance.com. All rights reserved.